page_title: Nifurtimox
section_title: Manufacturing and availability
hierarchical_section_title: Nifurtimox / Manufacturing and availability
caption_attribution_description: English: Image of nifurtimox and eflornithine
context_page_description: Nifurtimox, sold under the brand name Lampit, is a medication used to treat Chagas disease and sleeping sickness. For sleeping sickness it is used together with eflornithine in nifurtimox-eflornithine combination treatment. In Chagas disease it is a second-line option to benznidazole. It is given by mouth.
  Common side effects include abdominal pain, headache, nausea, and weight loss. There are concerns from animal studies that it may increase the risk of cancer but these concerns have not be found in human trials. Nifurtimox is not recommended in pregnancy or in those with significant kidney or liver problems. It is a type of nitrofuran.
  Nifurtimox came into medication use in 1965. It is on the World Health Organization's List of Essential Medicines. It is not available commercially in Canada. It was approved for medical use in the United States in August 2020. In regions of the world where the disease is common nifurtimox is provided for free by the World Health Organization.
context_section_description: Nifurtimox is sold under the brand name Lampit by Bayer. It was previously known as Bayer 2502.
  Nifurtimox is only licensed for use in Argentina and Germany, where it is sold as 120-mg tablets. It was approved for medical use in the United States in August 2020.
caption: A bottle of nifurtimox
exif: {}